Skip to main content
. 2024 Mar 11;18(12):8683–8693. doi: 10.1021/acsnano.3c09450

Figure 5.

Figure 5

Genomic information on tissue and blood biopsy of cancer patients. (a) Tumor mutational burden (TMB) of cancer patients. (b) PD-L1 expression of cancer patients evaluated with tumor proportion score (TPS). (c) Heat map of variant allele frequency (VAF) of cancer patients with either tissue or blood biopsy. The size and color gradient of the box represent the VAF value. Patient 1’s tissue biopsy VAF values are PTEN Q171* (15.3%), MLL2 E156* (12.1%), RB1 L769 fs*23 (28.2%), TP53 V272 M (25.7%), and EGFR amplification. Patient 1’s blood biopsy VAF values are NFE2L2 E79Q (2.3%), ARID1A S1791 (0.61%), PTEN R130Q (3.1%), MLL2 Q928* (0.81%), RB1 Y756* (3.1%), TP53 V272 M (0.22%), and TP53 R209* (3.8%). Patient 2’s tissue biopsy VAF values are EGFR L858R (64.6%) and TP53 Y205* (49.9%). Patient 2’s blood biopsy VAF values are EGFR L858R (27.1%), ARID1A Q561* (0.1%), TP53 Y205* (2.8%), and EGFR amplification. Patient 3’s tissue biopsy VAF values are TP53 Q100* (15.9%) and NF1 c.4430 (16.6%). Patient 4’s tissue biopsy VAF values are KRAS G12D (7.2%) and STK11 Y60 fs (2.5%).